The Equity in Neuroscience and Alzheimer's Clinical Trials (ENACT) Act seeks to increase representation in Alzheimer's clinical trials among traditionally underrepresented groups. This bill would:

​

• Provide funding for the NIA to build trust among underrepresented populations by expanding education and outreach and increasing the diversity of clinical trial staff.

• Reduce the burden associated with participating in clinical trials by:

  • Funding new Alzheimer's Disease Research Centers (ADRCs) and increasing the number of Alzheimer's clinical trials in areas with high concentrations of underrepresented populations. ​

  • Requiring grant recipients to use community-based engagement strategies in their outreach to underrepresented populations.

​

​